Approaches in studying the pharmacology of Chinese Medicine formulas: bottom-up, top-down—and meeting in the middle

• Main Authors: Tao Huang, Linda L. D. Zhong, Chen-Yuan Lin, Ling Zhao, Zi-Wan Ning, Dong-Dong Hu, Man Zhang, Ke Tian, Chung-Wah Cheng, Zhao-Xiang Bian, for MZRW Research Group
• Format: Article
• Language: English
• Published: BMC 2018-03-01
• Series: Chinese Medicine
• Subjects: Bottom-up; Chinese medicine formula; Focused network pharmacology; Pharmacometabolomics; Top-down
• Online Access: http://link.springer.com/article/10.1186/s13020-018-0170-4

Abstract Investigating the pharmacology is key to the modernization of Chinese Medicine (CM) formulas. However, identifying which are the active compound(s) of CM formulas, which biological entities they target, and through which signaling pathway(s) they act to modify disease symptoms, are still difficult tasks for researchers, even when equipped with an arsenal of advanced modern technologies. Multiple approaches, including network pharmacology, pharmaco-genomics, -proteomics, and -metabolomics, have been developed to study the pharmacology of CM formulas. They fall into two general categories in terms of how they tackle a problem: bottom-up and top-down. In this article, we compared these two different approaches in several dimensions by using the case of MaZiRenWan (MZRW, also known as Hemp Seed Pill), a CM herbal formula for functional constipation. Multiple hypotheses are easy to be proposed in the bottom-up approach (e.g. network pharmacology); but these hypotheses are usually false positives and hard to be tested. In contrast, it is hard to suggest hypotheses in the top-down approach (e.g. pharmacometabolomics); however, once a hypothesis is proposed, it is much easier to be tested. Merging of these two approaches could results in a powerful approach, which could be the new paradigm for the pharmacological study of CM formulas.